BUSINESSJul 16 · 03:03 UTCSCMP CHINAJulie Zhang

Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals

Mainland China institutional fund managers have increased investments in Hong Kong-listed biotech stocks due to attractive valuations and rising cross-border licensing deals. E Fund Management acquired a 7% stake in Biocytogen Pharmaceuticals by purchasing additional shares.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

E Fund ManagementorganizationBiocytogen Pharmaceuticalsorganizationcross-border licensing dealstopicgene-editing biotechnologytopicHong Kong biotechnology stockstopicMainland China institutional fund managersorganization

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJul 16 · 03:03 UTC
Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals
BUSINESSJun 30 · 03:00 UTC
Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge
BUSINESSJun 30 · 03:00 UTC
Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge
BUSINESSMay 31 · 08:15 UTC
AI firm MiniMax prepares for mainland China listing after shares surge in Hong Kong
BUSINESSJun 2 · 10:30 UTC
AI, biotech and new energy likely targets of HKIC yuan fund
BUSINESSJul 13 · 03:17 UTC
Chinese hard tech giants see value surge in first half as global investors pour in capital